Atem Capital: Triumvira Immunologics Announces the End of Series A; Total to Approx. $100M

Triumvira Immunologics, an Austin-based company, Xcell Therapeutics, is a clinical-stage company that develops novel, targeted, autologous, and allogeneic T-cell therapeutics. These therapies co-opt natural biology to treat solid tumors. It completed a Series A extension, bringing the total round up to about $100m. The Series A extension featured new investors, including significant participation from B Capital [...]